Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://www.kiromic.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
KRBP Latest News
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Scans taken six months post-treatment sho.
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). UPMC is a world-renowned healthcare system that employs some of the nation's top clinicians and.
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets' Life Science Investor Forum in a Fireside Chat format, hosted by VirtualInvestorConferences.com, on March 7th, 2024. Date: March 7, 2024 Time: 11:00 a.m. Eastern time Link: https://bit.l.
What type of business is Kiromic BioPharma?
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
What sector is Kiromic BioPharma in?
Kiromic BioPharma is in the Healthcare sector
What industry is Kiromic BioPharma in?
Kiromic BioPharma is in the Biotechnology industry
What country is Kiromic BioPharma from?
Kiromic BioPharma is headquartered in United States
When did Kiromic BioPharma go public?
Kiromic BioPharma initial public offering (IPO) was on 16 October 2020
What is Kiromic BioPharma website?
https://www.kiromic.com
Is Kiromic BioPharma in the S&P 500?
No, Kiromic BioPharma is not included in the S&P 500 index
Is Kiromic BioPharma in the NASDAQ 100?
No, Kiromic BioPharma is not included in the NASDAQ 100 index
Is Kiromic BioPharma in the Dow Jones?
No, Kiromic BioPharma is not included in the Dow Jones index
When does Kiromic BioPharma report earnings?
The next expected earnings date for Kiromic BioPharma is 14 August 2024